Company to webcast in­­vestor event, Sunday, De­cem­ber 6 at 8:30 p.m. ET

Orlando, FL (Press Release) – bluebird bio, Inc. (NASDAQ:BLUE), a clin­i­cal-stage com­pany com­mit­ted to devel­op­ing poten­tially trans­for­ma­tive gene ther­a­pies for severe ge­netic dis­eases and T cell-based im­mun­o­therapies for cancer, an­nounced that pre-clinical data from its anti-BCMA on­col­ogy pro­gram were pre­sented by bluebird bio scientists at the 57th American Society of He­ma­tol­ogy Annual Meeting.

“We be­lieve the unique science and trans­la­tional gene ther­apy plat­forms we have built dif­fer­en­ti­ate bluebird bio in the on­col­ogy field and have the poten­tial to yield im­por­tant new ther­a­pies for patients living with can­cer. Our three on­col­ogy posters at …

A SWOG trial shows bor­tez­o­mib, lena­lido­mide, and dexa­meth­a­sone delays recurrence and lengthens life for myeloma patients, indicating a possible new standard of care

Portland, OR (Press Release) – The addi­tion of bor­tez­o­mib to a standard two‐drug regi­men for myeloma patients sig­nif­i­cantly lengthened the time before their cancer returned, and sig­nif­i­cantly lengthened their lives, according to new clin­i­cal trial results announced today.

The ran­dom­ized, phase III trial, conducted by SWOG, a publicly funded inter­na­tional cancer clin­i­cal trials network, compared the effectiveness of two drug regi­mens in patients undergoing their first round of treat­ment …

Triplet regi­men resulted in sig­nif­i­cantly im­proved pro­gres­sion-free survival compared to standard of treat­ment

Summit, NJ (Press Release) – Celgene Corpo­ra­tion (NASDAQ:CELG) today announced that the addi­tion of bor­tez­o­mib to REVLIMID (lena­lido­mide) and low-dose dex­a­meth­a­sone (RVd), the standard of myeloma ther­apy, sig­nif­i­cantly im­proved pro­gres­sion-free survival (PFS) compared to lena­lido­mide and low-dose dex­a­meth­a­sone (Rd) in patients newly-diagnosed with multiple myeloma. The phase 3 study was conducted by SWOG, a publicly funded inter­na­tional cancer clin­i­cal trials network and presented at the 57th American Society of Hematology Annual Meeting.

In the 471-patient study, patients receiving RVd achieved a median PFS of 43 months compared to a median PFS of …

• Kyprolis Plus Dexamethasone Doubled Progression-Free Survival to More Than 18 Months Versus Velcade Plus Dexamethasone in Patients With Relapsed Multiple Myeloma
• First Head-to-Head Study Comparing two Proteasome Inhibitors

Thousand Oaks, CA (Press Release) – Amgen (NASDAQ:AMGN) today announced that The Lancet Oncology published results from the pivotal Phase 3 head-to-head ENDEAVOR study com­par­ing Kyprolis^® (car­filz­o­mib) plus dex­a­meth­a­sone to Velcade^® (bor­tez­o­mib) plus dex­a­meth­a­sone in patients with re­lapsed multiple myeloma. The data showed that patients treated with Kyprolis plus dex­a­meth­a­sone achieved pro­gres­sion-free survival (PFS) of 18.7 months compared to 9.4 months in those receiving bor­tez­o­mib plus dex­a­meth­a­sone (HR=0.53; 95 per­cent CI: 0.44,0.65 p<0.0001), a current standard of care in re­lapsed multiple myeloma. …

Data Confirm Efficacy and Safety of Kyprolis Combination Across Range of Patient Populations

Thousand Oaks, CA (Press Release) - Amgen (NASDAQ: AMGN) today announced the presentation of new key data eval­u­ating Kyprolis^® (car­filz­o­mib) -based regi­mens in patients with re­lapsed multiple myeloma. The data showed Kyprolis in com­bi­na­tion with dex­a­meth­a­sone sig­nif­i­cantly extended disease pro­gres­sion com­pared to bor­tez­o­mib plus dex­a­meth­a­sone across a range of dif­fi­cult-to-treat pop­u­la­tions, specifically those with high risk and pre­vi­ously treated disease. The analyses were presented during the 57th Annual Meeting and Exposition of the American Society of Hematology (ASH) in Orlando, Fla.

Data analyzed in three presentations across patient subgroups from the Phase …

Application Based on Pivotal Head-to-Head ENDEAVOR Study Showing Kyprolis Plus Dexametha­sone Doubled Progression-Free Survival Compared to Velcade^® (Bortezomib) Plus Dexamethasone

Thousand Oaks, CA (Press Release) – Amgen (NASDAQ: AMGN) today announced the sub­mission to the European Medicines Agency (EMA) of a Variation to the Marketing Authorization Application (MAA) to expand the indi­ca­tion for Kyprolis^® (car­filz­o­mib) in com­bi­na­tion with dexa­metha­sone for the treat­ment of adult patients with multiple myeloma who have received at least one prior ther­apy.

The appli­ca­tion is based on results from the Phase 3 head-to-head ENDEAVOR study in which patients with multiple myeloma treated with Kyprolis plus dexa­metha­sone achieved superior pro­gres­sion-free survival (PFS) compared to those receiving Velcade® (bor­tez­o­mib) plus …

• ELOQUENT-2 extended follow-up analysis of Empliciti in com­bi­na­tion with lena­lido­mide and dex­a­meth­a­sone (Rd) dem­onstrated a 44% rel­a­tive im­prove­ment in pro­gres­sion-free sur­vival at three years; re­­sults con­sis­tent with pivotal two year analysis
• Empliciti com­bi­na­tion had a median delay of one year in time to next treat­ment com­pared to Rd alone
• Pre-specified interim analysis for over­all sur­vival found a pos­i­tive trend favoring the Empliciti com­bi­na­tion versus Rd alone (HR 0.77; p=0.0257)

Princeton, NJ (Press Release) – Bristol-Myers Squibb Com­pany (NYSE:BMY) to­day pre­sented extended follow-up data and a pre-specified interim over­all sur­vival (OS) analysis of Empliciti in com­bi­na­tion with Revlimid^® (lena­lido­mide) and dex­a­meth­a­sone (ERd) in patients with re­lapsed or re­frac­tory mul­ti­ple myeloma from ELOQUENT-2. The follow-up data dem­onstrated that Empliciti in com­bi­na­tion with Rd had an im­prove­ment in pro­gres­sion-free sur­vival (PFS) with a hazard ratio (HR) of 0.73 (95% CI: 0.60, 0.89; p=0.0014) versus Rd alone. This re­­sult was con­sis­tent …